- Home
- DD vs ILMN Comparison
DD vs ILMN Comparison
Compare DD & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DD | ILMN |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2B | 20.4B |
| IPO Year | 2016 | 2000 |
Fundamental Metrics
Financial Performance| Metric | DD | ILMN |
|---|---|---|
| Price | $45.50 | $116.78 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 14 | 17 |
| Target Price | $62.07 | ★ $124.24 |
| AVG Volume (30 Days) | ★ 4.0M | 1.9M |
| Earning Date | 05-12-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | N/A | ★ 170.87 |
| EPS | N/A | ★ 5.45 |
| Revenue | ★ $20,397,000,000.00 | $4,343,000,000.00 |
| Revenue This Year | $6.91 | $6.52 |
| Revenue Next Year | $3.85 | $5.49 |
| P/E Ratio | ★ N/A | $22.26 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.34 | $68.70 |
| 52 Week High | $83.40 | $155.53 |
Technical Indicators
Market Signals| Indicator | DD | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 40.40 | 34.71 |
| Support Level | $42.47 | $114.88 |
| Resistance Level | $52.66 | $135.68 |
| Average True Range (ATR) | 1.32 | 4.50 |
| MACD | -0.69 | -0.21 |
| Stochastic Oscillator | 28.20 | 1.62 |
Price Performance
Historical ComparisonAbout DD DuPont de Nemours Inc.
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the healthcare, water, construction, automotive, aerospace, and printing and packaging industries. Healthcare and water will generate the majority of profits.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.